Treating ADHD in psychosis: What does the evidence say about safety?

Minimalist,Transparent,Venn,Diagram,–,Yellow,And,Orange,Circle,Overlapping

How safe is it to treat ADHD in people with schizophrenia spectrum disorders? New long-term data offers pragmatic reassurance, but also some warnings.

[read the full story...]

Physical health side effects of psychotropic medication: holistic prevention and management

Medicine warning sign, beware of drugs side effects, vector design of medical precaution illustration

From weight gain to heart rhythm changes, sexual dysfunction to sleep problems — the physical side effects of psychiatric drugs are vast, complex, and often overlooked. This blog distils key insights from a new Lancet Commission published today; to help clinicians and patients make safer, more informed prescribing decisions.

[read the full story...]

Probiotics for bipolar disorder and schizophrenia

feature

Mary Butler explores a recent randomised controlled trial of probiotic formulations for patients with bipolar disorder or schizophrenia spectrum disorder.

[read the full story...]

Psychotropic medication during pregnancy: new umbrella review finds no convincing evidence of adverse health outcomes for the baby

Featured

Flo Martin summarises a recent umbrella review which finds that we still have limited knowledge about the safety of psychotropic drug use in pregnancy.

[read the full story...]

Lamotrigine in the maintenance treatment of bipolar disorder

Lamotrigine, an anticonvulsant drug, is licensed in the United States for the maintenance treatment of bipolar I disorder and in the UK to prevent depressive episodes in bipolar disorder. Hashimoto and colleagues (2021) performed a Cochrane Intervention Review to explore whether lamotrigine is effective and safe compared to the most established maintenance treatment, lithium, and placebo.

Michael Ostacher critically appraises and summarises a recent Cochrane systematic review, which presents the latest best evidence on the efficacy of lamotrigine in the maintenance treatment of bipolar disorder.

[read the full story...]

Expertise from outside the Academy: tapering off antidepressants

Senior,Man,Holding,Pharmaceutical,Pills,Over,Isolated,Background,With,Open

Mark Horowitz considers a recent article written by Adele Framer, Founder of SurvivingAntidepressants.org, which describes how best to help people who are tapering off antidepressants.

[read the full story...]

First-hand experiences of taking antipsychotics: findings from a large online survey

christina-victoria-craft-WHSnkIwWpec-unsplash

Georgie Buswell summarises a cross-sectional study, which used open questions to try and understand people’s lived experiences of taking antipsychotic drugs.

[read the full story...]

Experience of psychotropic medication and decision-making

laurynas-mereckas-1TL8AoEDj_c-unsplash

Jennifer Rose Oulton reviews a qualitative study that explores the experiences of psychotropic medication use and decision-making for adults with learning disabilities and their carers.

[read the full story...]

“Where I End And You Begin”: A personal commentary on Russo’s ‘Through the eyes of the observed’ #PsychDrugDebate

Screen Shot 2018-07-23 at 12.59.20

Sarah Carr shares her own experiences of psychiatric medication and provides a critical reading of Jasna Russo’s new #PsychDrugDebate paper: ‘Through the eyes of the observed: re-directing the research on psychiatric drugs’.

[read the full story...]

How should we redirect research on psychiatric drugs? #PsychDrugDebate

image001-1

Alison Faulkner dissects the new McPin Foundation Talking Point Paper by Jasna Russo entitled: Through the eyes of the observed: re-directing research on psychiatric drugs.

Follow #PsychDrugDebate today on Twitter for further discussion about this vital issue.

[read the full story...]